Akela Pharma repeating Fentanyl inhalant safety study at FDA request

MONTREAL - Akela Pharma Inc. (TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S. Food and Drug Administration. Akela said Tuesday it remains on track to make regulatory submissions in 2010....More